ACP Offers Guidance on Antibiotic Duration for Common Infections
ACP recommends limiting antibiotic treatment duration to 5 days for COPD exacerbations and acute uncomplicated bronchitis.
ACP recommends limiting antibiotic treatment duration to 5 days for COPD exacerbations and acute uncomplicated bronchitis.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate in patients with COPD, regardless of exacerbation history, reduced exacerbation rates compared with the use of glycopyrrolate/formoterol fumarate.
Patients with chronic obstructive pulmonary disease (COPD) who have higher levels of HbA1c are at increased risk for hospital admission for acute exacerbations.
Researchers conducted a retrospective analysis of patients with COPD who were hospitalized and mechanically ventilated.
Switching from non-extra fine multi-inhaler triple therapy to single-inhaler extra-fine inhaled triple therapy improved regional ventilation to the small airways in patients with COPD.
In the first 30 days following an exacerbation of chronic obstructive pulmonary disease, there is an increased risk of cardiovascular adverse events.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
The DYNAGITO trial investigated the effectiveness of dual bronchodilation with fixed-dose tiotropium/olodaterol for reducing exacerbations of COPD.
Serologically assessed collagen remodeling plays a key role in the severity of COPD, as determined by airflow limitation and dyspnea, as well as in disease outcomes.